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Abstract. Injectable drug delivery systems (DDS) such as particulate carriers and water-soluble polymers
are being used and developed for a wide variety of therapeutic applications. However, a number of
immunological risks with serious clinical implications are associated with administration of DDS. These
immunological events can compromise the efficacy and safety of these systems by changing the
pharmacokinetics, biodistribution and targeting capability of DDS, and by inducing hypersensitivity
reactions. Antibodies induced by administration of DDS can be directed against the carrier material, the
drug and/or targeting ligands associated with the DDS. Complement activation and opsonization of DDS,
which may or may not be associated with antibody formation, may lead to accelerated clearance,
hypersensitivity reactions and formation of membrane attack complexes resulting in premature release of
the drug. Also platelets have been reported to play a role in DDS immunogenicity. Despite our curtailed
understanding of the relationships between physicochemical characteristics and immunogenicity of DDS,
several risk factors have been identified. Insight into these factors should be employed in the
development of novel DDS with low immunological risk.
KEY WORDS: antibody response; complement activation; drug delivery; hypersensitivity;
immunogenicity; liposomes; platelet activation; polymers.
INTRODUCTION
Injectable drug delivery systems (DDS) play an increas-
ingly important role in the administration of therapeutic
drugs since more of these systems are becoming commercially
available for a wide variety of applications. There are many
different types of DDS (e.g. polymer-based nanoparticles and
microparticles, lipid-based nanocarriers, water-soluble poly-
mer–drug conjugates, etc.) and they offer several advantages
over conventional dosage forms. In particular, controlled
release and targeting of active substances (small molecules,
proteins or genes) to the desired site of action is being
exploited to improve the delivery at the target site and avoid
body sites which are sensitive to toxic drug actions (1–7).
Liposomal DDS like Doxil and Ambisome have been on the
market already for decades, whereas other liposomal drugs
are in various stages of clinical development (8,9). Also
several peptide-loaded PLGA-based microparticles are avail-
able for the treatment of prostate cancer and other diseases,
while PLGA nanoparticles are being developed for the
(targeted) delivery of proteins, DNA and vaccines (6).
Furthermore, efficient anticancer drugs based on nanosized
conjugates of linear hydroxypropyl methacrylamide (HPMA)
copolymers, various molecular and supramolecular structures
of the HPMA copolymers and polymer micelles, conjugated
with biologically active proteins, low-molecular-weight drugs
and/or targeting ligands, have been developed (10,11).
Remarkably, little attention has been paid to the
potential immunogenicity, i.e. the capability of a substance
or device to elicit an immune response, of injectable DDS.
Whereas the immunostimulatory effects of delivery systems
have been well documented and exploited in the vaccine
delivery field (12–14), the unwanted immunostimulatory
effects of the same or similar carriers when used as DDS
have received much less attention. At first instance this may
not be surprising as the major drives in this field are the drug
and the disease to be treated. Therefore most investigators
focus on kinetic and therapeutic improvements and drug-
related toxicity of the products, rather than the immunolog-
ical risks associated with the administration of the DDS.
However, adverse immunological effects associated with the
application of DDS may pose serious risks to patients.
Immunogenicity of DDS can have severe clinical impli-
cations, such as reduced efficacy, immune responses after
repeated administration of a DDS (containing the same or a
different drug), or acute reactions. There is an urgent need to
increase our understanding of the physicochemical character-
istics that determine immunological reactions against inject-
able DDS already in clinical use or development, such as
liposomes, poly(lactic-co-glycolic acid) (PLGA) based sys-
tems and hydroxypropyl methacrylate copolymer (HPMA)–
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drug conjugates (15–17). Here we will review the literature on
immunological risks associated with the use of injectable
DDS. Our survey is primarily focused on specific antibody-
mediated responses. Immunotoxicity of DDS, which has been
extensively reviewed elsewhere (7,18–22), is also addressed.
Causes and consequences of immunological responses against
carriers, encapsulated drugs and targeting ligands will be
described and illustrated with examples. Moreover, relation-
ships between physicochemical characteristics of DDS immu-
nological risks associated with their use will be discussed.
ANTIBODIES AGAINST DRUG DELIVERY SYSTEMS
Antibodies Against the Carrier Material
Data on antibody responses against DDS are available
mainly for liposomes (23). Lipid A-containing liposomes
administered with Freund’s incomplete adjuvant (FIA, a
mineral oil) in animals has been reported to induce antibodies
against phosphatidyl choline and other phospholipids (24,25)
as well as cholesterol if incorporated in large amounts (71 mol
%) (26–28). Although anti-lipid antibodies in principle can
cross-react with endogenous lipids, these antibodies are
unlikely to interact with cell surfaces because these are
sterically protected by coverage with large molecules such as
glycolipids and proteins (23,29,30). However, formation of
antibodies against liposomes may have major implications for
the pharmacokinetic profile of liposomal carriers, in particular
through complement activation (7,31) and opsonization (32).
The above-mentioned studies on the immunogenicity of
liposomes and liposomal lipids were conducted in the
presence of adjuvants. Although this may not be representa-
tive for the administration of liposomes in a therapeutic
context, recent publications show evidence of antibody
(mainly IgM) responses in mice and rats against non-
adjuvanted PEGylated liposomes intended for therapeutic
use, resulting in rapid blood clearance (33–39). Antibody
responses were shown to be maintained in T cell-deficient
animals but not in B cell deficient or splenectomized animals,
pointing to a T cell-independent mechanism requiring mar-
ginal zone B cells in the spleen (34,36,37). Furthermore, IgM
was claimed to clear PEGylated compounds far more rapidly
and complete than IgG antibodies do, since the pentameric
structure of IgM promotes the formation of larger immune
complexes and activates complement more efficiently than
IgG does (35).
Although the literature describing anti-DDS antibodies
is largely restricted to liposomal carriers, there is no
fundamental reason why antibodies would not be formed
against other DDS, including polymeric DDS. Polymers by
definition contain repeat units, which may trigger B cell
activation and hence antibody production (40,41), as dis-
cussed below. Indeed the formation of anti-PEG antibodies
has been observed in patients treated with PEGylated
proteins and found to be correlated with accelerated clear-
ance and reduced activity of the drugs (42,43). Also, HPMA
copolymers and other water-soluble polymers have shown to
be immunogenic in mice, although antibody levels are
generally low (44,45). Antibodies against HPMA–drug con-
jugates were reported to be predominantly, though not
exclusively, directed to the drug (45). Conjugation of avidin
to HPMA did not affect the moderate IgM response against
the polymer when administered to mice in the presence of
alum (46). Repeated administration of empty polyacryl starch
microparticles in mice did not induce detectable antibody
levels (47).
Encapsulated drugs may increase or reduce antibody
responses against the carrier. When human serum albumin
was entrapped in the above-mentioned polyacryl starch
microparticles, repeated administration in mice resulted in
antibodies directed not only against the protein but also
against the particle matrix (47). Semple et al. showed that
loading of PEGylated liposomes with antisense oligonucleo-
tide or plasmid DNA enhanced the anti-PEG antibody
responses in several mouse strains (37). Interestingly, this
effect was found to be independent of the presence of
immunostimulatory CpG motifs in the drug. In contrast,
PEGylated liposomes containing encapsulated doxorubicin
induced lower IgM levels in rats than empty PEGylated
liposomes did, likely due to the toxicity of doxorubicin for
immune cells (33).
Antibodies Against Drugs
It is well known that conjugation of haptens (i.e., small
molecules that can act as B cell epitopes if bound to a carrier)
to proteins can render them immunogenic, no matter whether
or not the hapten is an endogenous compound. For instance,
steroid hormones and cholesterol were shown to become
immunogenic in rabbits by conjugation to human albumin
(48); paracetamol (acetaminophen) conjugated to horseradish
peroxidase elicited anti-paracetamol antibodies in mice (49).
Whereas these examples illustrate the immunogenicity of
haptens conjugated to proteins, thereby providing them with
T-helper epitopes, the conjugation of haptens with non-
proteinaceous carriers (which lack T-helper epitopes) can
also make them immunogenic. Examples include acrylamide–
dinitrophenyl (DNP) conjugates (50–52), dextran-trinitro-
phenyl (TNP) and polyacrylamide–TNP conjugates (53),
and various HPMA–drug conjugates (45).
Not only chemical conjugation but also noncovalent
association of small molecules in a particulate carrier can
render them immunogenic. Incorporation of gangliosides in
lipid A-containing liposomes was shown to generate anti-
ganglioside antibodies in mice (54). Lipid A-containing
liposomes with the cholesterol precursor squalene induced
anti-squalene antibodies in mice (55), showing that even very
hydrophobic compounds, which presumably are buried in the
liposomal bilayer, can become immunogenic by liposomal
association.
Particulate systems are widely used in vaccinology to
increase the immunogenicity of intrinsically immunogenic
proteins, such as bacterial and viral antigens. So, the
encapsulation of foreign proteins in particulate DDS is likely
to increase their immunogenicity. For instance, a significant
increase in IgG1 levels following subcutaneous administration
in mice of foreign proteins or protein–hapten conjugates
encapsulated in PLGA particles was observed in comparison
with the levels after administration of the free compounds
(56). Ovalbumin covalently coupled to liposomes elicited
higher antibody levels than soluble ovalbumin (57). Many
other examples can be found in the vaccine literature (12–14).
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Although the immunogenicity of soluble self proteins is
low or absent, practically all recombinant human proteins are
immunogenic in patients (58,59). As discussed later, the
immunogenicity of self proteins can be enhanced by presen-
tation in aggregated or particulate form (see below). Hence,
association of recombinant human proteins with a particulate
DDS may be a risk factor for immunogenicity.
Encapsulation of drugs in DDS does not always lead to
increased anti-drug antibody levels, e.g. when the drug is
cytotoxic or immunosuppressive. Tardi et al. showed that the
antibody response in mice to ovalbumin covalently attached
to the surface of liposomes was fully suppressed when
doxorubicin was co-encapsulated in the liposomes (57). The
immunosuppressive effect of doxorubicin has been ascribed
to the toxic action of doxorubicin on macrophages or B cells
(33,57).
In particular cases the incorporation of a drug into a
delivery system can reduce its immunogenicity. This has been
reported for recombinant human factor VIII (rFVIII).
Approximately 15–30% of the patients treated with rFVIII
develop inhibitory antibodies that neutralize the protein’s
activity. For most of these patients rFVIII is a non-self protein
because they do not produce endogenous factor VIII.
Ramani et al. reported that hemophilic mice treated with
subcutaneous injections of phosphatidyl serine (PS)-contain-
ing liposomal rFVIII (non-self protein) produced lower total-
and inhibitory titers compared to mice having received rFVIII
alone (60). This effect was ascribed to steric shielding of the
immunodominant PS-binding site of rFVIII and an immuno-
modulatory effect of PS (61). Incorporation of rFVIII in
PEGylated PS-containing liposomes resulted in a further
reduction of rFVIII immunogenicity (62).
Reduced anti-drug antibody formation has also been
observed for polymer–protein conjugates as compared to the
free proteins (44–46). Several (self and non-self) proteins
conjugated to high-molecular-weight (ca. 30 kDa) copolymer
HPMA induced lower antibody titers in mice as compared to
the free proteins. When the proteins were conjugated with
PEG (Mw 5,000) the immune response was also reduced
albeit to a lesser extent, while conjugation to low-molecular-
weight (ca. 3 kDa) HPMA did not reduce the immunogenic-
ity of the proteins (45). It was hypothesized that antigenic
epitopes of proteins bound to the high-molecular-weight
HPMA copolymer were shielded and thereby had become
unavailable for recognition by the immune system, a mech-
anism that has been suggested for PEGylated proteins as well
(58).
The above-mentioned examples illustrate that the immu-
nogenicity of a drug when incorporated in or conjugated with
a DDS is largely unpredictable. When a drug is associated
with a DDS its immunogenicity can be induced, enhanced as
well as reduced.
Antibodies Against Targeting Ligands
DDS can be actively targeted to the desired site of action
by covalently coupled targeting ligands, such as antibodies
and receptors (1–5,63). A few reports have shown that this
can lead to antibody responses against the ligand.
Philips and Dahman observed that free mouse IgG2a
was not immunogenic after repeated injection in mice,
whereas immunoliposomes (containing 0.9 mol% mouse
IgG2a) induced anti-IgG2a antibodies (IgG1) impairing the
targeting capacity of the liposomes in vivo (64). The presence
of 5 mol% PEGylated phospholipid in the liposomal bilayer
enhanced rather decreased the anti-IgG2a response.
Harding et al. (65) attached chimerized mouse IgG
(C225, containing human Fc) covalently to the hydrazide
end-groups of the PEG chains which were grafted onto the
surface of liposomes. Whereas repeated intravenous admin-
istration of soluble C225 did not induce antibodies, a single
injection of the immunoliposomes triggered an immune
response in rats which was reflected in C225-specific (mainly
Fc-specific) IgG titers. Subsequently injected immunolipo-
somes or free C225 were rapidly cleared from the blood
circulation. This demonstrates that coupling of the IgG to
liposomes renders it immunogenic.
Antibodies Against Linkers
In principle, a chemical linker to conjugate a drug or
targeting ligand to a DDS, or to PEGylate a DDS, can give
rise to the creation of new immunogenic epitopes, but
evidence of linker-induced immunogenicity is lacking in the
public domain. Since chemical linkers are sterically ‘trapped’
between the DDS and the drug or ligand moiety, especially in
case of bulky ligands like antibodies, linker-induced immu-
nogenicity may not be a major issue in most cases.
If the linker is proteinaceous in nature, e.g. avidin-biotin
spacers which are commonly used in research, the linker
might not only be immunogenic itself but also provide T-
helper epitopes enhancing antibody responses against the
DDS or incorporated drugs.
Why Do DDS Elicit Antibodies?
The previous sections have illustrated that antibodies can
be formed against drug carriers, encapsulated drugs or
targeting ligands. In this section we will explain why DDS-
mediated drug delivery can induce antibody formation.
Practically all molecules or materials, including those
made by our own body (i.e. self antigens), are antigenic (i.e.,
capable of reacting with components of the immune system).
This is even true for compounds lacking any obvious
functional groups, such as squalene and fullerenes (55,66).
This implies that any molecule or DDS contains structures (B
cell epitopes) that can be recognized by specific human B cell
receptors (BCRs). Recognition of an epitope by a BCR in
itself, however, is not sufficient to induce a strong antibody
response; otherwise all endogenous molecules and structures
in our body would be continuously attacked by our own
immune system. Apparently an additional trigger is needed to
render a molecule immunogenic (i.e., able to elicit an immune
response). As will be explained below, the immunogenicity of
a molecule depends both on its structure and on how it is
presented to the immune system (Table I).
As many of the DDS/drug combinations for which
immunogenicity has been described are non-protein based,
and thus lack T cell epitopes, antibody formation should
occur via a T cell independent mechanism. One common
mechanism likely responsible for the formation of DDS-
induced antibodies is the creation of multiple B cell epitopes
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by the DDS formulation, which is an intrinsic property of
most DDS. Closely spaced B cell epitopes in repetitive arrays
can directly activate B cells via a mechanism known for T cell-
independent type 2 (TI-2) antigens (see (40) and references
therein). TI-2 antigens must be repetitive to cluster and
crosslink BCRs on the surface of the B cell. This BCR
clustering initiates a complex signaling pathway, such as the
activation of Bruton’s tyrosine kinases, which mediate B-cell
proliferation leading to activation, proliferation and formation
of antibodies against the antigen (40,67,68). The immune
system has evolved to rigorously react to highly dense (spacing
between 5–10 nm), repetitive epitope arrays that normally are
present only on the surface of viruses and some bacteria, but
not on mammalian cell surfaces (67). BCRs on the surface of
resting B cells have been estimated to be about 40 nm apart;
BCR crosslinking by epitope arrays can be achieved rapidly,
since BCRs are ‘floating’ in the cell membrane of B cells and
can be recruited at a velocity of ca. 300 nm/s (40).
Classical examples of TI-2 antigens include bacterial
capsular polysaccharides used as vaccines (e.g., pneumococcal
and meningococcal vaccines), and haptens (i.e., small mole-
cules that can act as B cell epitopes if bound to a carrier)
conjugated to polymers. In 1976, Dintzis et al. showed that
acrylamide substituted with 12 to 16 dinitrophenyl (DNP)
haptens were very immunogenic, while free DNP as well as
polymers containing less haptens per polymer did not elicit
antibodies (50). Additional investigations confirmed that the
immunogenicity of haptenated polymers is determined by a
minimum hapten valency of 10–20 (51,52), but depends on
the size of the polymers as well, requiring a threshold
molecular mass of about 100 kDa (51). Moreover, ample
evidence points to epitope spacings between 5–10 nm being a
potent trigger for B cell activation (50,51,67,69–73). This
principle has also been proposed as a mechanism for the
immunogenicity of aggregated proteins (58,59). Brunswick et
al. demonstrated that conjugation of anti-BCR (anti-IgD or
anti-IgM) antibodies, or Fab fragments thereof, to dextran
made them 1,000-fold more potent (as compared to the
unconjugated antibodies) in B cell activation (74). This was
later shown to be a representative model for the activation of
B cells by TI-2 antigens conjugated to polymers (75).
Chackerian et al. (72) demonstrated that the density of
self proteins on the surface of virus-like particles (VLPs) is
crucial for the induction of an antibody response against these
proteins. The closer the spacing, the higher was the resulting
antibody response, being optimal at an epitope spacing of 5–
10 nm, in line with that reported for polymer–hapten
conjugates. Unlike self proteins, non-self proteins were shown
to elicit antibodies also when not conjugated to VLPs (72,73).
This suggests that “non-selfness” is a risk factor by itself,
whereas a self antigen, like a small molecule, requires
multimeric presentation to become immunogenic (Table I).
With the epitope array concept in mind, B cell activation
and subsequent antibody responses can be expected after
administration of particulate DDS or polymer–drug conju-
gates that contain highly repetitive B cell epitopes, as
schematically illustrated in Fig. 1. Such epitope arrays can
be created by the carrier material itself (e.g., the phospholipid
head groups on liposomal surfaces, and polymers which by
definition contain repeat units), the encapsulated or conju-
gated drugs if presented in arrays, or ligands attached to the
carrier. For instance, common ligand concentrations on
liposomal surfaces are between 0.5–2 mol% of the lipid
content, corresponding to ca. 250–1,000 ligands on each
100-nm liposome with an average spacing between 5–10 nm.
This perfectly matches the optimum epitope density for B cell
activation and may explain the antibody responses against
liposomal ligands (64,65), as described above.
The examples of polymer–hapten conjugates have illus-
trated how non-immunogenic molecules can be turned into
immunogenic structures. It can be anticipated that presenta-
tion of the same molecules on particulate carriers will show
even stronger effects, as the immune system has evolved to
recognize particulate materials as foreign (14). Indeed,
insoluble polyacrylamide-trinitrophenyl (TNP) beads and
dextran-TNP beads with high hapten densities activated B
cells much more strongly than their soluble counterparts
(polymer–TNP conjugates) did (53). Moreover, polymer–
drug conjugates such as HPMA based systems seem less
immunogenic than particulate drug carriers. These observa-
tions are also consistent with the conception that large, rigid
systems are more immunogenic than smaller, more flexible
structures (40,71). The general validity of this proposition,
however, remains to be established. Another explanation for
the low apparent immunogenicity of currently used conju-
gates is that the polymers are usually much smaller than the
reported threshold size of 100 kDa required for raising an
antibody response (51).











LMW compounds − + ++
Polymers (not protein based) + +a ++
Self proteins −/+ +++ +++
Non self proteins + +++ ++++b
Ranging from − (practically no risk) to ++++ (very high risk); intrinsic immunomodulatory properties of the antigens are not considered in the
table, but obviously will affect the risk
a Intrinsic property of these compounds
b Properties of viruses and bacteria
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Besides the particulate character and the presence of
repetitive B cell epitopes, additional risk factors can be
provided by the presence of adjuvants. In particular, patho-
gen-associated molecular patterns (PAMPs) form an impor-
tant adjuvant category (76), which includes Toll like receptor
(TLR) ligands such as LPS or bacterial DNA (CpG)
sequences. These adjuvants are stimulators of the innate
immune system, capable of activating B cell clones specific for
other antigens. Whereas TLR ligands are being utilized to
enhance the potency of vaccines, they should be avoided in
DDS but might be present as impurities or contaminants.
Furthermore, TI-2 antibody responses can be rendered T cell
dependent (TD) if T-helper epitopes are contained in the
carrier, e.g. when the carrier is protein based or contains
protein based drugs or ligands. In theory this would result in
higher and more persistent antibody levels, because—besides
direct activation of B cells—other TD mechanisms and
generation of immunological memory may happen.
An important consequence of antibody formation
against DDS is activation of the complement. Moreover,
complement has been reported to enhance the BCR cross-
linking signal (40). Complement activation, however, can also




The complement system plays an important role in the
defense against pathogens, such as viruses and bacteria. One
of the major functions of the complement is to label
pathogens for subsequent elimination from the host. Depend-
ing on its properties, a DDS may be ‘seen’ as a pathogen and
eliminated by the complement system. Consequences of
DDS-induced complement activation include opsonization of
the DDS resulting in rapid clearance by macrophages,
hypersensitivity reactions and formation of membrane attack
complexes (7,31,77), the latter being relevant for vesicular
DDS.
There are three pathways leading to complement activa-
tion (see (7,41) for details and references), all of which may
be induced by DDS related factors: (1) the classical pathway,
initiated by antibodies bound to the surface of the DDS, (2)
the alternative pathway, initiated by constituents of DDS
surfaces, and (3) the lectin pathway, activated by carbohy-
drate-recognizing proteins bound to the DDS surface (Fig. 2).
DDS-mediated complement activatin occurs predominantly
via the first two pathways (78–81) and the lectin pathway will
come into play for mannosylated DDS (63).
All three pathways involve activation of C3 by C3
convertase, which cleaves C3 that is bound to the particle
(pathogen or DDS) surface in the fragments C3a and C3b. C3a
plays a role in hypersensitivity reactions (see below). C3b and its
fragment iC3b are the most abundant and important comple-
ment proteins. Interaction of surface bound C3 fragments with
Fig. 2. DDS-mediated activation pathways of the complement system
(adapted from (81)). For further details see text.
Fig. 1. Schematic illustration of the interaction of molecules (orange bullets, which can be drugs, targeting
ligands, or repeat units of a polymer) with B cell receptors (BCRs, surface immunoglobulins on B cells).
Interaction of the free, soluble molecules with BCRs leads to toleragenic signals (A). Interaction of the
same molecules linked to a polymeric DDS (B) or a particulate DDS (C) with the BCRs leads to
crosslinking of BCRs. The latter triggers a complex signaling pathway, such as Bruton’s tyrosine kinase
activation, eventually resulting in B cell activation.
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the C3 receptor on the surface of phagocytic cells leads to
phagocytosis of these immune complexes (41,79,82,83). For
liposomal DDS the activated complement can cause liposome
destabilization by the formation of a membrane attack complex
(MAC or C5b-9) (7,81). MAC formation induces leakage and
release of the liposomal contents, resulting in increased toxicity
or reduced activity, caused by higher drug concentrations at
non-target sites or lower drug concentrations at the target sites,
respectively (41,79).
The classical pathway is initiated by binding of IgM and
IgG to foreign particles and subsequent binding of C1q to
surface-bound IgM or IgG (41,80,84,85). IgM associated with
PEGylated liposomes may work synergistically with comple-
ment components (C3b, iC3b) on the enhancement of
liposome uptake by liver macrophages through receptor
mediated endocytosis. Complement activation is strongly
amplified through a cascade of enzymatic reactions. Anti-
bodies, especially IgM, trigger and amplify this cascade, even
in small amounts, implicating that the antibody mediated
process may be the predominant mechanism (35,86).
In 1997 Alving et al. demonstrated that the activation of
complement by cholesterol-containing liposomes involves the
classical rather than alternative pathway (87). However, later
reports indicate that liposomes can activate complement via
both the classical and the alternative pathway. Liposomal
complement activation is promoted by large size, polydisper-
sity, positive or negative surface charge and high (>45%)
cholesterol content (31,87). It has been shown that negatively
charged liposomes activate complement primarily via the
classical pathway (86,88) and positively charged liposomes do
this via the alternative pathway (88,89), whereas neutral
liposomes are poor activators of complement (88,90).
Complement activation via the classical pathway by
anionic liposomes has been reported to occur through
antibody-independent binding of positively charged C1q to
the surface of the DDS through electrostatic interactions
(84,91). However, a recent study showed that the structure of
the negatively charged moieties on the liposomes, rather than
the negative charge per se, is crucial for complement
activation (92). Complement activation by PEGylated lip-
osomes has been reported to require the presence of
negatively charged compounds such as PEG-phosphatidyl
ethanolamine and is possibly initiated by naturally circulating
anti-PEG antibodies or in an antibody independent fashion
(7,90,93).
Besides liposomes, isobutylcyanoacrylate nanoparticles
have been reported to activate complement in vitro. Surface
modification of these particles by coating with a high-density
(‘brush’ conformation) layer of chitosan or dextran reduced
complement activation, whereas a low-density (‘mushroom’
conformation) layer did not (94). In the same study dextran
sulfate layers were found to be poor activators of comple-
ment, but at the same time promoted the adsorption of serum
proteins. Various other charged nanoparticles have been
shown to be potent compliment activators in vitro as
compared to neutral ones (95–97).
Accelerated Clearance
The clearance of liposomes and other DDS from the
blood circulation occurs after recognition by cells belonging
to the mononuclear phagocyte system (MPS) (81,85,98,99).
Also hepatocytes seem to play a role in the clearance of
liposomes from the blood circulation (100). PEG attached to
DDS was initially thought to act as an inert steric barrier for
attachment of opsonins, thereby leading to decreased recog-
nition of the DDS by cells of the MPS, resulting in prolonged
circulation (34,101). However, it has been shown that after
repeated injection PEGylated liposomes are cleared much
faster than after the first administration, a phenomenon
known as the accelerated blood clearance (ABC) effect
(33,35,36,38,42,102–104). The second dose of PEGylated
liposomes accumulate mainly in the liver, but also to a lesser
extent in the spleen, which implies involvement of Kupffer
cells and fixed macrophages of the spleen in the accelerated
blood clearance of subsequent doses (105–108).
The ABC effect can be divided into two phases: the
induction phase, following the first injection and resulting in
formation of serum factors, and the effectuation phase,
following the second or subsequent injections in which
PEGylated liposomes are rapidly cleared (106,107). The
effect was reported to be saturable and mediated by a serum
factor. It is thought that complement activation, caused by
anti-PEG IgM elicited by the first dose, initiates the ABC
phenomenon (37,39,104), whereas a direct effect of the
liposomes on the intrinsic phagocytic activity of Kupffer cells
was excluded (103).
According to Wang et al., induction of the ABC effect is
not only determined by the PEG coating but also by the size
and surface charge of the first dose of liposomes (104).
However, Laverman and coworkers have reported that the
ABC effect is a general characteristic of liposomes and does
not depend on the presence of PEG or on the liposome size,
but is related to lipid dose and dosing interval (106,109). This
may suggest that pre-existing anti-lipid antibodies (23) or
other serum components are (also) involved in the ABC effect.
Early capture of liposomes by these serum components might
explain why in general the first part of the concentration—time
curve, especially at low liposome doses, is steeper than the
following part.
Hypersensitivity Reactions
Hypersensitivity reactions triggered by intravenous ad-
ministration of DDS have been observed in the clinic for
liposomal drugs (e.g., Doxil, Daunoxome), emulsions (e.g.
taxol formulated in Cremophor EL), and polymeric micelles
(e.g. Genexol, taxol formulated in PLA-PEG micelles)
(31,110,111). Although the Genexol-mediated reactions were
ascribed to intrinsic properties of paclitaxel, they are more
likely related to the PLA-PEG micelles used in this formu-
lation to solubilize the drug.
These anaphylactoid reactions are a consequence of
activation of the complement system via the classical and/or
the alternative pathway, and are called complement activa-
tion-related pseudoallergy (CARPA) (31). As opposed to
IgE-mediated allergy requiring presensitization, CARPA
occurs at first exposure of the DDS and its severeness usually
declines after repeated administration (31,108,112–114). It is
therefore unlikely that DDS-induced antibody formation
plays a role in CARPA, but the involvement of pre-existing
antibodies cannot be excluded. CARPA involves anaphyla-
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toxin (C3a and C5a) liberation which causes an increase of
inflammatory cells in the blood circulation. The incidence of
CARPA varies between 5–45% of patients treated with DDS,
which is much higher than classical anaphylactic reactions to
drugs, for example penicillin allergy occurs in less than 2% of
the treated patients (31). CARPA can induce serious clinical
conditions which show cardiovascular, respiratory and cuta-
neously related symptoms, such as bradycardia, arrhythmia,
tachypnea and flushing.
Platelet Activation
Platelets are known as primary actors in hemostasis. In
addition, accumulating evidence points to platelets as impor-
tant players in the innate immune response (115–117). It has
been reported that platelets might play a bridging role
between innate and adaptive immune response (115), or act
as innate inflammatory cells in an immune response (116).
Platelets express a variety of receptors, such as FcγR, TLR4
and TLR2, and can secrete several immune-stimulatory
products, such as cytokines and chemokines (115,117,118).
Reports about DDS-induced platelet aggregation are
conflicting. It has been demonstrated that liposomes are able
to induce (119–121) as well as inhibit (122,123) aggregation of
platelets. The types of phospholipids in the membrane of the
liposomes (124–126) and the surface charge of these vesicles
(119–123) seem to play a role in the procoagulatory
properties. Platelet aggregation in vitro and rat thrombosis
in vivo was reported to be induced by carbon nanoparticles
(127), whereas neutral and PEG-coated surfactant-based
nanoparticles did not induce platelet activation in vitro
(128). Liposomes with a negative surface charge have been
reported to increase as well as inhibit platelet aggregation
(120–123).
Little is known about the mechanisms of DDS-induced
platelet activation (19). One of the signaling molecules that
might play a role is the platelet-activating factor (PAF). PAF
is a proinflammatory phospholipid secreted by mast cells,
monocytes and macrophages. It interacts with the PAF
receptor expressed on cells such as platelets, monocytes and
eosinophils. This can lead to platelet aggregation and a
number of inflammatory effects, such as chemotaxis and
degranulation (124,126), as well as anaphylaxis (129,130).
Aggregation of platelets may also be directly enhanced
by the presence of immune complexes on the DDS surface.
Platelets are able to recognize these immune complexes
through their Fc receptor, FcγRIIa. Aggregated platelets
stimulate the production of C3a and C5a, factors of the
complement system that play a role in CARPA (41).
SUMMARIZING DISCUSSION
We have surveyed the literature showing that usage of
DDS can induce antibody formation and other immunolog-
ical events, which may result in serious clinical consequences,
as summarized in Table II. Antibody-mediated accelerated
blood clearance leads to reduced therapeutic concentrations
of the drug in the blood circulation resulting in a lower
bioavailability and efficacy. The opposite can occur via
complement-mediated lysis of the DDS, giving rise to burst
release. This will result in increased blood concentrations and
altered biodistribution of the drug, and thereby higher toxicity.
Hypersensitivity reactions as a result of complement activation
can induce serious clinical conditions with cardiovascular,
Table II. Immunological Reactions Against Injectable DDS and their Clinical Consequences
Phenomenon Mediatora Effect on efficacy and safety
Accelerated blood clearance (ABC) Antibodies Decreased efficacy
Complement Liver/spleen toxicity
Membrane attack complex (MAC) formation Complement Increased toxicity
(Antibodies) Reduced efficacy
Complement activation-related pseudoallergy (CARPA) Complement Hypersensitivity reactions
(Antibodies)
Platelet aggregation Platelets Thrombus formation
(Antibodies)
(Complement)
aMediators between brackets may or may not be involved
Table III. Risk Factors for Immunological Responses Against
Injectable DDS
Immune response Risk factors
Innate Particulate systems
TLR ligands (e.g. LPS, CpG)
Ligands targeted to phagocytes/APCs
(e.g. mannose)
Antibody production At least 10–20 epitopes per
conjugate/particle
High density (5–10 nm spacing)
of epitopesa




Complement activation Positive or negative surface charge
Large size and high polydispersityc
High (>45%) cholesterol contentc
Intravenous administration
Platelet activationc Positive or negative surface charge
Intravenous administration
aDerived from the delivery system itself (e.g. phospholipids, PEG),
or from associated drugs or ligands
bBased on literature about therapeutic proteins
cBased on literature about liposomal DDS
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respiratory and cutaneous symptoms. Platelet activation can
enhance innate and adaptive immune responses, and induce
platelet aggregation. The latter could give rise to thrombus
formation and thereby obstruction of blood vessels, resulting in
life-threatening situations. However, the impact of platelet
activation in immunogenicity of DDS is yet unclear and
requires further studies.
Although a complete picture of the immunological risk
of DDS is currently lacking, a number of risk factors known
to affect the immunological safety of DDS have been
identified (Table III). Still, clinical data on the immunogenic-
ity of DDS are scarce, probably because only few products
have reached the clinical stage and most of these are
anticancer drugs. This drug category is unlikely to give strong
antibody responses, firstly because immune compromised
cancer patients receiving these drugs are unlikely to form
antibodies and secondly because cytotoxic drugs have been
shown to reduce antibody formation. On the other hand,
complement activation induced by liposomal doxorubicin and
colloidal taxol formulations is commonly seen.
For DDS containing drugs other than immunosuppres-
sive agents, one should consider the risk for antibody
formation in the design of the DDS. Multiple epitope arrays
clustered at the surface of DDS form a particular risk factor
for immunogenicity and should be avoided if possible.
Ligands such as mannose that are recognized by APCs should
especially be avoided, except for vaccination purposes
(63,131), although data showing enhanced immune responses
when used therapeutically are lacking. The particulate
character of many DDS makes them prone to be recognized
as foreign by immune cells and the complement system.
Soluble polymer–drug conjugates seem less likely to induce
antibody formation. Although PEG was initially considered
to be an immunologically inert polymer, also PEGylated DDS
have been shown to induce antibodies and to be involved in
complement activation, accelerated clearance and hypersen-
sitivity reactions. So, PEGylation is no guarantee for an
immunologically safe DDS.
The route of administration has not been systematically
studied but almost certainly has a major influence on the risk
of immunological responses. Whereas subcutaneous adminis-
tration may be the injection route which most easily generates
antibodies, complement activation and platelet activation are of
particular clinical relevance upon intravenous administration.
Fig. 3. Simplified schematic presentation of the interrelationship between the immunological reactions discussed in the text.
The dashed arrows represent possible, not yet confirmed pathways for platelet activation. For further details see text.
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Also other factors such as the release kinetics, release
mechanism, as well as the stability of the drug and the carrier
are likely to play a yet unidentified role in the immunogenic-
ity of DDS. For instance, dependent on the residence time of
a DDS, during release and decomposition of the carrier new
surface structures will be created which may be more (or less)
immunogenic than the intact system. Moreover, labile protein
drugs in DDS are susceptible to aggregation (132), which may
generate additional risk.
Antibody formation against DDS typically occurs after
one or a few administrations, as opposed to antibodies against
recombinant human therapeutic proteins which usually show
up after chronic treatment (58,59), despite the similar
mechanisms thought to be involved. The observed difference
in the kinetics of antibody formation could be due to the fact
that in DDS the drugs are deliberately concentrated in
colloidal carriers, which are known to have immune stimula-
tory activities and—almost by definition—contain epitope
arrays. In contrast, therapeutic proteins normally contain only
small amounts of immunogenic impurities such as aggregates
and therefore have a much lower probability of eliciting an
immune reaction.
In conclusion, apart from all the benefits such as
controlled release and drug targeting, DDS can cause
immunological events, which may compromise their pharma-
cokinetics, biodistribution and targeting capability, and there-
by their efficacy and safety. Reported immune reactions
against DDS include antibody formation, complement acti-
vation, and platelet activation, phenomena which may be
interrelated as schematically illustrated in Fig. 3. Most of the
available literature data relate to liposomal and HPMA-based
DDS, but it is very unlikely that other DDS are immunolog-
ically inert. As detailed knowledge about the precise charac-
teristics associated with immunogenicity of DDS is lacking
and the scarce literature data are in part conflicting,
prediction of the immunogenicity of DDS is currently very
difficult. Still, some risk factors associated with immunoge-
nicity are known (Table III) and should not be overlooked
early in the development of novel DDS. In parallel, further
research on the causative factors of immunogenicity of DDS
is essential to better permit the rational design of immuno-
logically safe DDS.
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